These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34011628)

  • 1. Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.
    Ng J; Barral S; De La Fuente Barrigon C; Lignani G; Erdem FA; Wallings R; Privolizzi R; Rossignoli G; Alrashidi H; Heasman S; Meyer E; Ngoh A; Pope S; Karda R; Perocheau D; Baruteau J; Suff N; Antinao Diaz J; Schorge S; Vowles J; Marshall LR; Cowley SA; Sucic S; Freissmuth M; Counsell JR; Wade-Martins R; Heales SJR; Rahim AA; Bencze M; Waddington SN; Kurian MA
    Sci Transl Med; 2021 May; 13(594):. PubMed ID: 34011628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Adeno-Associated Virus-mediated rescue of function in a mouse model of Dopamine Transporter Deficiency Syndrome.
    Illiano P; Bass CE; Fichera L; Mus L; Budygin EA; Sotnikova TD; Leo D; Espinoza S; Gainetdinov RR
    Sci Rep; 2017 Apr; 7():46280. PubMed ID: 28417953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine Transporter Deficiency Syndrome (DTDS): Expanding the Clinical Phenotype and Precision Medicine Approaches.
    Ng J; Barral S; Waddington SN; Kurian MA
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacochaperoning in a
    Asjad HMM; Kasture A; El-Kasaby A; Sackel M; Hummel T; Freissmuth M; Sucic S
    J Biol Chem; 2017 Nov; 292(47):19250-19265. PubMed ID: 28972153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile Parkinsonism-Dystonia.
    Aguilar JI; Cheng MH; Font J; Schwartz AC; Ledwitch K; Duran A; Mabry SJ; Belovich AN; Zhu Y; Carter AM; Shi L; Kurian MA; Fenollar-Ferrer C; Meiler J; Ryan RM; Mchaourab HS; Bahar I; Matthies HJ; Galli A
    Elife; 2021 May; 10():. PubMed ID: 34002696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia.
    Kurian MA; Zhen J; Cheng SY; Li Y; Mordekar SR; Jardine P; Morgan NV; Meyer E; Tee L; Pasha S; Wassmer E; Heales SJ; Gissen P; Reith ME; Maher ER
    J Clin Invest; 2009 Jun; 119(6):1595-603. PubMed ID: 19478460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infantile parkinsonism-dystonia: a dopamine "transportopathy".
    Blackstone C
    J Clin Invest; 2009 Jun; 119(6):1455-8. PubMed ID: 19504720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood.
    Ng J; Zhen J; Meyer E; Erreger K; Li Y; Kakar N; Ahmad J; Thiele H; Kubisch C; Rider NL; Morton DH; Strauss KA; Puffenberger EG; D'Agnano D; Anikster Y; Carducci C; Hyland K; Rotstein M; Leuzzi V; Borck G; Reith ME; Kurian MA
    Brain; 2014 Apr; 137(Pt 4):1107-19. PubMed ID: 24613933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of cocaine stimulation and reward by reintroducing wild type dopamine transporter in adult knock-in mice with a cocaine-insensitive dopamine transporter.
    Wu H; O'Neill B; Han DD; Thirtamara-Rajamani K; Wang Y; Gu HH
    Neuropharmacology; 2014 Nov; 86():31-7. PubMed ID: 24835281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra.
    Schöls L; Reimold M; Seidel K; Globas C; Brockmann K; Hauser TK; Auburger G; Bürk K; den Dunnen W; Reischl G; Korf HW; Brunt ER; Rüb U
    Brain; 2015 Nov; 138(Pt 11):3316-26. PubMed ID: 26362908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missense dopamine transporter mutations associate with adult parkinsonism and ADHD.
    Hansen FH; Skjørringe T; Yasmeen S; Arends NV; Sahai MA; Erreger K; Andreassen TF; Holy M; Hamilton PJ; Neergheen V; Karlsborg M; Newman AH; Pope S; Heales SJ; Friberg L; Law I; Pinborg LH; Sitte HH; Loland C; Shi L; Weinstein H; Galli A; Hjermind LE; Møller LB; Gether U
    J Clin Invest; 2014 Jul; 124(7):3107-20. PubMed ID: 24911152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurodevelopmental and synaptic defects in DNAJC6 parkinsonism, amenable to gene therapy.
    Abela L; Gianfrancesco L; Tagliatti E; Rossignoli G; Barwick K; Zourray C; Reid KM; Budinger D; Ng J; Counsell J; Simpson A; Pearson TS; Edvardson S; Elpeleg O; Brodsky FM; Lignani G; Barral S; Kurian MA
    Brain; 2024 Jun; 147(6):2023-2037. PubMed ID: 38242634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study.
    Kurian MA; Li Y; Zhen J; Meyer E; Hai N; Christen HJ; Hoffmann GF; Jardine P; von Moers A; Mordekar SR; O'Callaghan F; Wassmer E; Wraige E; Dietrich C; Lewis T; Hyland K; Heales S; Sanger T; Gissen P; Assmann BE; Reith ME; Maher ER
    Lancet Neurol; 2011 Jan; 10(1):54-62. PubMed ID: 21112253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying dominant-negative actions of a dopamine transporter variant in patients with parkinsonism and neuropsychiatric disease.
    Herborg F; Jensen KL; Tolstoy S; Arends NV; Posselt LP; Shekar A; Aguilar JI; Lund VK; Erreger K; Rickhag M; Lycas MD; Lonsdale MN; Rahbek-Clemmensen T; Sørensen AT; Newman AH; Løkkegaard A; Kjærulff O; Werge T; ; Møller LB; Matthies HJ; Galli A; Hjermind LE; Gether U
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells.
    Beerepoot P; Lam VM; Salahpour A
    J Biol Chem; 2016 Oct; 291(42):22053-22062. PubMed ID: 27555326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
    Jourdain S; Morissette M; Morin N; Di Paolo T
    J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
    Hong J; Sha S; Zhou L; Wang C; Yin J; Chen L
    Cell Death Dis; 2015 Jul; 6(7):e1832. PubMed ID: 26203861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Caenorhabditis elegans model to study dopamine transporter deficiency syndrome.
    Illiano P; Lanzo A; Leo D; Paglione M; Zampi G; Gainetdinov RR; Di Schiavi E
    Eur J Neurosci; 2017 Jan; 45(1):207-214. PubMed ID: 27519790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.